Analysis of the Efficacy and Survival of Third-line Treatment in Advanced Non-small Cell Lung Cancer
Chinese Journal of Lung Cancer, 06/14/2012
Shao L et al. – Advanced non–small cell lung cancer (NSCLC) patients who never smoke, have good PS scores, and have good disease control from the first– and second–line therapies could benefit more in third–line treatment. Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) therapy showed increased progression free survival (PFS) compared with single and doublet agents.